Coronary percutaneous revascularization procedures

Series
Coronary interventions
Status
Published
Date
Number of report
019

Ask the expert

(we accept only company emails)

Report presents summary of reimbursement situation for number of coronary percutaneous revascularization methods.

Sample pages are provided for an older version of the report. Before delivery to the client, the report is updated to the current state (e.g., 2022 coding, tariffs, and policy considerations). 

Procedures, covered in the report include:

  • Percutaneous coronary balloon angioplasty (including plain and drug-coated balloons)
  • Percutaneous coronary angioplasty with stenting using bare metal, drug-eluting and bioresorbable stents
  • Mechanical thrombectomy
  • Mechanical atherectomy

Analysis is provided for three indications: stable angina, unstable angina and acute myocardial infarction.

Day case procedures are not considered in the report. 

Report includes essential information about reimbursement and national funding, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Manufacturers of devices for coronary percutaneous revascularization include:

  • Aachen Resonance (PTCA catheter CORONARY)
  • Abbott Vascular (Coronary stent XIENCE Alpine, Coronary stent XIENCE Xpedition, Coronary stent graft GRAFTMASTER RX)
  • Accura (Coronary stent Accura Decent S, Coronary stent Decent, PTCA catheter Positsoon)
  • Acrostak (PTCA catheter ACROSS HP™, PTCA catheter GRIP™)
  • amg International (Coronary stent Pico Elite, Coronary stent ICROS, PTCA catheter ISTAR)
  • Amnis Therapeutics (Biological membrane-covered coronary stent AneugraftDx)
  • Andramed (Coronary stent AndraStent)
  • AngioScore (PTCA catheter AngioSculpt®)
  • Argon Medical (Fixed Core Straight & PTFE Coated Guidewires)
  • Arthesys (Coronary stent Cygnus II, PTCA catheter Maya)
  • Asahi Intecc (PTCA catheter Zenyte EX)
  • B. Braun (Coronary stent Coroflex® ISAR NEO, Coronary stent Coroflex® Blue Neo, PTCA catheter SeQuent® Please NEO, PTCA catheter SeQuent® Neo, PTCA catheter NSE Alpha, PTCA catheter SeQuent® Please OTW)
  • Balton (Coronary stent BIOSS, Coronary stent BIOSS EXPERT, PTCA catheter RIVER, PTCA catheter BOTTLE)
  • Bentley InnoMed (Coronary stent graft BeGraft)
  • Biomerics (PTCA Balloon catheters)
  • Biotronik (Coronary stent Magmaris, Coronary stent Orsiro, PTCA catheter Pantera LEO, PTCA catheter Pantera Pro)
  • Boston Scientific (Coronary stent Promus PREMIER™, Coronary stent ION™, PTCA catheter Apex™, PTCA catheter Emerge™)
  • Capture Vascular (Thrombectomy catheter MegaVac)
  • Cardionovum (Coronary stent Precision® series, Coronary stent Xlimus series)
  • Cardiva (Flagship XS. PTCA coronary guide)
  • Celonova (Coronary stent COBRA PzF™, Coronary stent CATANIA™)
  • Clearstream Technologies  (Coronary stent SatinFlex™, Coronary stent ClearFlex-X®, PTCA catheter NIMBUS PICO® µ, PTCA catheter Nimbus Salvo™)
  • Comed (Coronary stent Deimos™, Coronary stent Miranda™, PTCA catheter Oberon™)
  • Conic Vascular (PTCA balloon catheter NC CLEVER)
  • Control Medical Technology (Thrombectomy catheter ASPIRE)
  • Cordis (PTCA catheter EMPIRA®, PTCA catheter EMPIRA® NC)
  • Degania Silicone (Coronary stent, PTCA catheter)
  • Elixir Medical (Coronary stent DESyne®, Coronary stent DESyne® BD)
  • Endocor (Coronary stent SEQUENCE™, Coronary stent CONSTELLATION™, PTCA catheter CARDIOGLIDE™ HP, PTCA catheter CARDIOGLIDE™ CTO,Thrombectomy catheter PHANTOM 7F™, Thrombectomy catheter PHANTOM™ 5F)
  • Eucatech (Coronary stent eucaLimus, Coronary stent Ccflex, PTCA catheter eucaVI)
  • Eurocor (Coronary stent E-MAGIC PLUS, Coronary stent MAGICAL®, PTCA catheter DIOR)
  • Goodman Medical Ireland Limited (PTCA balloon Lacrosse, PTCA Y connector OKAY II)
  • HEXACATH (Coronary stent Titan Optimax, Coronary stent TITAN2, PTCA catheter Mistral SC, PTCA catheter Mistral NC)
  • IMeSI Italia (PTCA catheter Apollo Fluens, PTCA catheter Apollo HP)
  • InSitu Technologies (Coronary stent Celosia™, Coronary stent Direct-Stent®, Coronary stent graft Direct-Stent®, PTCA catheter Arriva™ PTCA)
  • InspireMD (Coronary stent Mguard, Coronary stent MGuard Prime)
  • Intelligent Kinetics (PEGASUS PTCA Balloon Catheter, ABARIS Rapamycin-Eluting Coronary Stent System, CORPAX Drug Eluting Balloon)
  • iVascular (Coronary stent Angiolite, Coronary stent Architect, Thrombectomy catheter Capturer, Coronary stent graft Prograft, PTCA catheter NC Xperience)
  • Japan Lifeline (PTCA Guide Wires, PTCA Balloon Catheters)
  • Kaneka (PTCA Balloon Catheter IKAZUCHI Zero, IKAZUCHI-Rev, IKAZUCHI X Hyp, RAIDEN3, Ryusei)
  • LVD Biotech (PTCA Guide wires)
  • Medas Inc (Coronary stent Inspire™, Coronary stent Brave™)
  • Medinol (Coronary stent NIRxcell™, PTCA catheter Assure™)
  • Merit Medical Systems (Catheter guidewire Worley™, Catheter guidewire Ostial PRO®)
  • Micro Science Medical AG (Drug Eluting PTCA Balloon Catheter MSM® DECO, BMS Stainless Steel Stent Coronary Implant System MSM® CIS BARE  (Stent))
  • MicroPort (PTCA catheter FOXTROT™ NC, PTCA catheter JIVE™)
  • Minvasys (Coronary stent Nile® Pax, Coronary stent Nile Croco®, PTCA catheter Yangtze® µ, PTCA catheter Yangzte® NC)
  • Opsens (Pressure Wire OptoWire Deux)
  • Oscor (Balloon catheters, Stent delivery systems)
  • Ostial Corporation (Flash-C PTCA balloon dilatation catheters)
  • QualiMed (PTCA Balloon catheter)
  • Rontis Medical (Coronary stent Abrax™, Coronary stent Phoenix Pico™)
  • SIS Medical (PTCA catheter TIN®, PTCA catheter BEO NC®)
  • Stentys (Coronary stent Xposition S, Coronary stent MiStent SES®)
  • STI Laser (Coronary stents)
  • Svelte Medical Systems (Coronary stent SVELTE™)
  • Terumo (Coronary stent Ultimaster®, Coronary stent Kaname®, PTCA catheter Heartrail® II, PTCA catheter Accuforce®)
  • Tokai Medical Products (Jadeite PTCA balloon catheter)
  • Translumina (Coronary stent Yukon® Choice PC, Coronary stent Yukon® Choice 4DES,  PTCA catheter Cathy N° 4)
  • Tryton Medical (Coronary stent)
  • Vitalcor (CORONARY ARTERY PERFUSION CANNULA WITH BALLOON)
  • Wellinq (Coronary stent Track, Coronary stent Pioneer, PTCA catheter Protégé, PTCA catheter Protégé NC, PTCA catheter Force NC, PTCA catheter Everest)
  • Zeus (Covered Stents)

Table of content

1.    Introduction and summary
2.    Executive summary table
3.    Contents
4.    Abbreviations
5.    Methodology
6.    Reimbursement analysis in Austria

6.1.    Overview of the reimbursement system
6.2.    Reimbursement for coronary percutaneous revascularization procedures
6.2.1.    Procedure coding
6.2.2.    Diagnosis coding
6.2.3.    Payment mechanism and reimbursement tariffs
6.2.4.    Policy considerations by the LBI-HTA
7.    Reimbursement analysis in Belgium
7.1.    Overview of the reimbursement system
7.2.    Reimbursement for coronary percutaneous revascularization procedures
7.2.1.    Procedure coding
7.2.2.    Payment mechanism and reimbursement tariffs
7.2.3.    Policy considerations 
7.2.4.    Health technology assessments by KCE 
8.    Reimbursement analysis in Denmark
8.1.    Overview of the reimbursement system
8.2.    Reimbursement for coronary percutaneous revascularization procedures
8.2.1.    Procedure coding 
8.2.2.    Diagnosis coding
8.2.3.    Payment mechanism and reimbursement tariffs
8.2.4.    Policy considerations 
9.    Reimbursement analysis in England
9.1.    Overview of the reimbursement system
9.2.    Reimbursement for coronary percutaneous revascularization procedures
9.2.1.    Procedure coding 
9.2.2.    Diagnosis coding
9.2.3.    Payment mechanism and reimbursement tariffs
9.2.4.    Policy considerations 
9.2.4.1.    Specifics of commissioning of the procedure
9.2.4.2.    Health technology assessments by NICE
10.    Reimbursement analysis in France
10.1.    Overview of the reimbursement system
10.2.    Reimbursement for coronary percutaneous revascularization procedures
10.2.1.    Procedure coding 
10.2.2.    Diagnosis coding
10.2.3.    Payment mechanism and reimbursement tariffs
10.2.4.    Policy considerations by HAS
11.    Reimbursement analysis in Germany
11.1.    Overview of the reimbursement system
11.2.    Reimbursement for coronary percutaneous revascularization procedures
11.2.1.    Procedure coding 
11.2.2.    Diagnosis coding
11.2.3.    Payment mechanism and reimbursement tariffs
11.2.4.    Policy considerations by G-BA
12.    Reimbursement analysis in Italy
12.1.    Overview of the reimbursement system
12.2.    Reimbursement for coronary percutaneous revascularization procedures
12.2.1.    Procedure coding at national level
12.2.2.    Procedure coding at regional level (Emilia-Romagna, Lombardy, Veneto regions)
12.2.3.    Diagnosis coding
12.2.4.    Payment mechanism and reimbursement tariffs at national level
12.2.5.    Payment mechanism and reimbursement tariffs at regional level
13.    Reimbursement analysis in the Netherlands
13.1.    Overview of the reimbursement system
13.2.    Reimbursement for coronary percutaneous revascularization procedures
13.2.1.    Procedure coding 
13.2.2.    Diagnosis coding
13.2.3.    Payment mechanism and reimbursement tariffs
13.2.4.    Policy considerations by Dutch Healthcare Institute (СIN)
14.    Reimbursement analysis in Norway
14.1.    Overview of the reimbursement system
14.2.    Reimbursement for coronary percutaneous revascularization procedures
14.2.1.    Procedure coding 
14.2.2.    Diagnosis coding
14.2.3.    Payment mechanism and reimbursement tariffs
14.2.4.    Policy considerations 
15.    Reimbursement analysis in Sweden
15.1.    Overview of the reimbursement system
15.2.    Reimbursement for coronary percutaneous revascularization procedures
15.2.1.    Procedure coding 
15.2.2.    Diagnosis coding
15.2.3.    Payment mechanism and reimbursement tariffs
15.2.4.    Policy considerations
16.    Reimbursement analysis in Switzerland
16.1.    Overview of the reimbursement system
16.2.    Reimbursement for coronary percutaneous revascularization procedures
16.2.1.    Procedure coding 
16.2.2.    Diagnosis coding
16.2.3.    Payment mechanism and reimbursement tariffs
16.2.4.    Policy considerations
17.    Disclaimer

25

Apr 2022

On March 31, 2022, NHS Digital released HRG4+ Local Payment Grouper for 2022/23 for use from April 01, 2022. In general, there are significant changes in base HRG design. A total of 120 new HRGs were created, and multiple HRGs were removed, so the total number increased by 62 from 2,838 to 2,900.

Read more

15

Feb 2022

In January 2022, the Basque Office for Health Technology Assessment (OSTEBA) released an HTA report aiming to assess and compare the efficacy, effectiveness, and safety of the mechanical circulatory support devices most used in the healthcare setting for the treatment and prevention of cardiogenic shock, including Impella® devices, intra-aortic balloon pumps, and extracorporeal membrane oxygenation.

Read more

31

Jan 2022

On January 20, 2022, the Academy of Medical Royal Colleges (AoMRC) launched a consultation on the latest set of guidance (List 3) of the Evidence-based Interventions (EBI) Programme. EBI program develops guidance sets (Lists) for tests, treatments, and procedures based on recommendations from the Expert Advisory Committee and NICE assessments. Proposed List 3 covers 17 interventions across a range of medical specialties, including cardiology, ophthalmology, urology, and others. The deadline for comments submission is March 31, 2022.

Read more

17

Dec 2021

The Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) systematically evaluates healthcare technologies and practices from medical, economic, ethical, and social standpoints. The following assessments were initiated in the third quarter of 2021: ultrasound-guided arterial catheters insertion in adults, the basis for national guidelines for heart disease. The final reports will be published on the SBU website upon completion

Read more

15

Dec 2021

In 2015, the Federal Office for Public Health launched an HTA program intending to reassess the benefits already reimbursed by compulsory health insurance. The following ongoing re-evaluations are in progress: multigene expression tests in breast cancer, cardiac catheterization for coronary artery disease, invasive procedures for coronary artery disease, removal of osteosynthesis materials, etc.

Read more
(we accept only company emails)